YOLFTbeta
Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc

CTXR · NASDAQ · Healthcare / Biotechnology

0.5351USD+0.00 (+0.51%)

Price History

Full chart

Market Stats

Previous Close0.5324
Open0.54
Day Range0.4959 – 0.5494
52-Week Range0.469 – 2.19
Volume173.13K
Market Cap15.65M
P/E (TTM)0.00
Forward P/E0.32
EPS-1.75
Dividend Yield0.00%
Beta1.00
50-Day Avg0.5966
200-Day Avg0.7197

About

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Leonard L. Mazur
  • Employees23
  • Headquarters11 Commerce Drive, Cranford, NJ, United States, 07016, USA
  • Websitehttps://citiuspharma.com

Leadership

  • Mr. Leonard L. MazurCo-Founder, CEO, Chairman & Secretary · b. 1945
  • Mr. Myron Z. HolubiakCo-Founder & Executive Vice Chairman · b. 1947
  • Dr. Myron S. Czuczman M.D.Executive VP & Chief Medical Officer · b. 1960
  • Mr. Jaime BartushakChief Business Officer & CFO · b. 1968
  • Mr. Gary F. TalaricoExecutive Vice President of Operations · b. 1955
  • Ms. Ilanit AllenVice President of Investor Relations & Corporate Communications
  • Dr. Alan Lader Ph.D.Senior VP and Head of Clinical Operations & Quality Assurance
  • Mr. Dhananjay G. WadekarSenior Vice President of Business Strategy · b. 1954
  • Mr. Kelly Creighton Ph.D.Executive Vice President of Chemistry, Manufacturing & Controls
  • Mr. Nikolas BurlewExecutive Vice President of Quality Assurance

Financials

Income Statement

Currency: USD2011-09-302012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue---000000000000
Cost of Revenue---001.34K2.63K1.75K893152.36K164.87K179.68K194.32K209.61K214.25K
Gross Profit---00-1.34K-2.63K-1.75K-893-152.36K-164.87K-179.68K-194.32K-209.61K-214.25K
Operating Expense---1.15M3.23M7.45M9.98M13.79M15.60M17.56M23.37M33.14M36.54M41.79M38.31M
Operating Income-25.64K-19.62K-28.12K-1.15M-3.23M-7.45M-9.99M-13.79M-15.60M-17.71M-23.53M-33.32M-36.73M-42.00M-38.53M
EBITDA-24.93K-19.62K-28.12K--3.23M-7.45M-9.98M-13.79M-15.54M-17.56M-23.37M-33.14M-36.54M-38.64M-38.20M
Net Income-26.34K-22.01K-31.37K-1.27M-2.90M-8.30M-10.38M-12.54M-15.58M-17.55M-23.05M-33.64M-32.54M-39.14M-37.43M
R&D-705.81492.14K437.97K1.80M2.93M2.94M6.56M8.60M8.81M12.24M17.66M14.82M11.91M9.16M
Interest Expense02.39K3.25K07.50K8.99K850.79K15.84K16.44K15.67K10.84K251.40K--267.78K

Balance Sheet

Currency: USD2011-09-302012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets212135107.97K1.56M741.54K21.95M24.42M31.05M28.99M43.77M142.43M114.00M103.61M116.65M130.94M
Total Liabilities24.05K45.98K14.69K2.30M1.38M5.18M2.47M3.18M4.61M10.10M9.65M10.57M12.18M42.55M53.41M
Total Equity-23.84K-45.85K-14.69K-741.93K-635.21K16.77M21.95M27.87M24.38M33.67M132.18M102.83M90.83M70.08M67.55M
Cash21213554.39K1.55M676.14K294.35K3.20M9.18M7.89M13.86M70.07M41.71M26.48M3.25M4.25M
Total Debt18.49K17.05K3.21K600.00K-672.97K172.97K172.97K172.97K1.35M855.47K678.23K481.25K262.87K1.81M
Net Debt18.28K16.91K-51.18K-952.06K-676.14K378.62K-3.03M-9.01M-7.72M-12.51M-69.22M-41.03M-26.00M-2.99M-2.44M

Cash Flow

Currency: USD2011-09-302012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-20.78K-20.32K-20.60K-705.05K-2.39M-5.90M-7.97M-11.32M-12.44M-16.93M-24.25M-28.36M-29.06M-28.20M-26.55M
Investing Cash Flow--2.02-255.75K255.75K255.75K-2.13K-1.83K-1.83K-1.83K-40.01M---5.00M-5.75M
Financing Cash Flow18.49K20.25K20.47K2.26M1.51M5.26M10.88M17.30M11.15M22.90M120.47M31.27K13.83M9.97M33.30M
Capital Expenditure0002.13K2.13K2.13K2.13K1.83K1.83K1.83K40.01M0200
Free Cash Flow-20.78K-20.32K-20.60K-705.05K-2.39M-5.90M-7.97M-11.32M-12.44M-16.93M-64.26M-28.36M-29.06M-28.20M-26.55M
Dividends Paid---0-----------
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.03%100.00%100.00%100.01%264.97%100.00%100.00%100.00%100.00%
Dividend Paid to FCF---0.00%-----------

Earnings

Report DateDec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016May 15, 2017Aug 14, 2017Dec 13, 2017Mar 20, 2018May 11, 2018Aug 14, 2018Dec 11, 2018Feb 14, 2019May 15, 2019Aug 14, 2019Dec 16, 2019Feb 13, 2020May 14, 2020Aug 14, 2020Dec 16, 2020Feb 11, 2021May 13, 2021Aug 12, 2021Dec 15, 2021Feb 10, 2022May 12, 2022Aug 11, 2022Dec 22, 2022Feb 10, 2023May 12, 2023Aug 14, 2023Dec 29, 2023Feb 14, 2024May 14, 2024Aug 12, 2024Dec 27, 2024Feb 12, 2025May 14, 2025Aug 12, 2025Dec 23, 2025Feb 13, 2026May 15, 2026Aug 14, 2026
EPS Estimate---------------8.00-0.16-5.25-5.00-1.50-0.14-3.50-2.75-2.75-2.500.16-2.25-1.00-0.04-1.50-1.75-1.50-1.50-0.06-1.25-1.75-1.500.13-1.50-1.12-1.50-1.250.11-0.21-0.24-0.30-0.32-0.36
EPS Actual-10.28-4.16-9.57-9.98-13.30-8.75-18.66-13.28-11.09-0.55-0.49-0.43-0.38-0.44-4.75-0.16-5.50-5.00-5.00-0.16-3.75-3.25-2.75-1.75-0.15-1.00-1.25-0.02-1.50-1.25-1.50-1.25-0.02-1.75-1.50-1.75-0.06-1.25-1.50-5.80-1.30-1.27-0.80-0.11-0.38-0.95-0.34
Surprise--------------40.63%0.00%-4.76%0.00%-233.33%-14.29%-7.14%-18.18%0.00%30.00%-193.75%55.56%-25.00%50.00%0.00%28.57%0.00%16.67%66.67%-40.00%14.29%-16.67%-146.15%16.67%-33.93%-286.67%-4.00%-1254.55%-280.95%54.17%-26.67%-196.88%5.56%
Timing-----------After-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap15.65M
Enterprise Value5.84M
Trailing P/E0.00
Forward P/E0.32
PEG Ratio0.00
Price / Sales2.20
Price / Book0.24
EPS-1.75
Book Value2.43
Revenue (TTM)7.11M
Gross Profit (TTM)5.50M
EBITDA-53.85M
Profit Margin0.00%
Operating Margin-670.23%
Return on Equity-81.09%
Return on Assets-26.57%
Shares Outstanding27.45M
Shares Float26.96M
Beta1.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 2 analystsTarget 4.00
  • Strong Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
4.95%
Insiders
1.80%
Retail / Other
93.25%

Top Institutional Holders

  • Geode Capital Management, LLC
    246.16K0.90%
  • Vanguard Capital Management, LLC
    167.74K0.61%
  • Miller Financial Services LLC
    130.00K0.47%
  • Citadel Advisors Llc
    124.91K0.46%
  • Vanguard Fiduciary Trust Co
    77.75K0.28%
  • BlackRock Inc
    69.85K0.25%
  • HRT FINANCIAL LLC
    60.33K0.22%
  • Asset Advisory Group, INC.
    59.01K0.21%
  • UBS Group AG
    55.02K0.20%
  • Northern Trust Corp
    43.97K0.16%
  • Susquehanna International Group, LLP
    36.84K0.13%
  • BostonPremier Wealth LLC
    28.00K0.10%
  • LPL Financial Corp
    25.05K0.09%
  • State Street Corp
    23.27K0.08%
  • Jane Street Group LLC
    22.52K0.08%
  • XTX Topco Ltd
    21.30K0.08%
  • Arkadios Wealth Advisors
    20.00K0.07%
  • Two Sigma Investments LLC
    17.49K0.06%

Top Fund Holders

  • Fidelity Extended Market Index
    139.15K0.51%
  • Fidelity Series Total Market Index
    26.36K0.10%

Stock Splits

  • Nov 26, 20241:25
  • Jun 9, 20171:15